<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03380741</url>
  </required_header>
  <id_info>
    <org_study_id>CCR4868</org_study_id>
    <nct_id>NCT03380741</nct_id>
  </id_info>
  <brief_title>Lab-on-a-chip Detection of Cervical Cancer Tumour Markers</brief_title>
  <acronym>MODULAR</acronym>
  <official_title>Molecular Diagnostics Using a Novel Lab-on-a-chip and MRI for Detecting Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. George's NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to establish whether tumour markers measured from cytological samples can
      improve cervical cancer detection both prior to treatment and after treatment during follow
      up.

      All patients with presumed early cervical cancer referred to the Gynaecological Oncology Unit
      at The Royal Marsden Hospital and patients previously surgically treated for early cervical
      cancer with a suspected recurrence will be invited to participate.

      Women attending the Colposcopy Unit at St George's Hospital, with a normal cervix will be
      invited to participate.

      An endovaginal receiver coil has been designed and developed at the Institute of Cancer
      Research and Royal Marsden NHS Foundation Trust for use at high field strengths (3T).

      A cytology swab, similar to a smear test, will be used to collect a sample of cells to
      evaluate the presence of tumour markers.

      The presence of tumour markers will be measured by a lab-on-a-chip and polymerase chain
      reaction (PCR) testing system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cervical cytology: This will be done prior to MRI at an out-patient visit or at the scan
      visit in all study subjects with cancer. IN those patients with a normal cervix at
      colposcopy, the sample will be taken as part of the colposcopy examination. The procedure
      will be identical to that used for cervical smear testing and involves the insertion of a
      speculum and taking a swab from the cervix and/ or vaginal vault for tumour marker assessment
      on lab-on-a-chip. Additionally, the sample will be examined conventionally to assess
      cytology.

      MRI scan: For patients with primary disease, this will be done using an endovaginal
      technique. A ring design endovaginal coil will be inserted endovaginally around the cervix.
      It acts as a dedicated receiver, and the substantially improved signal enables high-spatial
      resolution images to be obtained (voxel size &lt; 0.5 mm3). In patients being followed up after
      definitive surgery, in whom recurrence is suspected, MRI will be done using a standard phased
      array technique if the cervix is absent. In both instances, the MRI sequences will be
      standard and involve the use of T2-W and diffusion weighted sequences in 3 orthogonal planes.
      Contrast agents will not be administered. Intramuscular antiperistaltic agents (20 mg
      hyoscine butylbromide) are used routinely for pelvic imaging.

      Histological analysis: Biopsies will be obtained from all patients with primary disease. This
      will be either a cone or LLETZ biopsy. In some cases with clearly visualized tumour due for
      radical hysterectomy, a punch biopsy may suffice for diagnosis.

      In patients with suspected recurrence, a biopsy will be obtained if feasible and a visible
      mass is evident on imaging. In cases without a visible mass, or if biopsy is not feasible,
      vault cytology will be use as the gold standard. In the absence of adequate histology or
      cytology for validating the presence or absence of tumour, the patient will be withdrawn from
      the study.

      Data Recording: Patient data will be recorded on case report forms. Patient data from case
      report forms will be recorded on a password protected study database. The MRI images will be
      placed onto the hospital picture archiving and communications system (PACS) and clinical
      reports will be available immediately to the referring clinicians.

      Good Clinical Practice: The trial will be conducted in compliance with the protocol, standard
      operating procedures, policies, local R&amp;D management guidance, Good Clinical Practice
      including the Research Governance Framework 2005 including the current Human Tissue Act,
      Human Tissue (Quality and Safety for Human Application) Regulations, the Medical Devices
      Regulations and Ionising Radiation (Medical Exposures) Regulations.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lab-on-a-chip agreement with PCR system</measure>
    <time_frame>20 months</time_frame>
    <description>To compare the agreement (sensitivity/specificity) between lab-on-a-chip system and PCR system in detecting tumour markers (HPV and cancer-specific gene overexpression) derived from patients with biopsy/cytology proven i) primary and ii) recurrent squamous or adeno cervical cancer and those from cytologically normal cervix.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary disease</measure>
    <time_frame>20 months</time_frame>
    <description>To determine the sensitivity of tumour markers (HPV and cancer-specific gene overexpression) derived from lab-on-a-chip system in patients with primary cervical cancer (versus histology as the gold standard).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent disease</measure>
    <time_frame>20 months</time_frame>
    <description>To determine the sensitivity of tumour markers (HPV and cancer-specific gene overexpression) derived from lab-on-a-chip system in patients with recurrent cervical cancer (versus histology as the gold standard).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory radiomic outcome</measure>
    <time_frame>20 months</time_frame>
    <description>To determine association/correlation between radiomic features of tumour identified on endovaginal MRI with tumour markers (HPV and cancer-specific gene overexpression).</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Group1</arm_group_label>
    <description>Tumour present on histology and MRI following biopsy/LLETZ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Tumour absent on MRI following biopsy/LLETZ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Tumour recurrence present at the vaginal vault on MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <description>Tumour recurrence absent at the vaginal vault on MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <description>Normal cervix at colposcopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Tumour markers detection</intervention_name>
    <description>Lab on a chip detection of tumour markers measured from vaginal/cervical cytology swab</description>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Cervical/vaginal cytology swab
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with presumed early cervical cancer referred to the Gynaecological Oncology
        Units at The Royal Marsden Hospital and patients previously surgically treated for early
        cervical cancer currently undergoing follow up with suspected cancer recurrence will be
        invited to participate.

        Women attending St George's Hospital colposcopy clinic, who are judged to have a normal
        cervix on colposcopy examination will be invited to participate.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â€¢ Patients with presumed early stage cervical cancer (squamous or adenocarcinoma on
             histology) being considered for curative surgery.

               -  Patients treated surgically for cervical cancer (squamous or adenocarcinoma on
                  histology) being followed-up for suspected recurrent disease.

               -  Patients with normal cervix at colposcopy examination.

        Exclusion Criteria:

          -  Ferromagnetic metal implants, claustrophobia (MRI incompatibility). Neuroendocrine or
             unusual histological subtypes. Abnormal cervix seen at colposcopy examination (for
             Normal cervix cohort).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ben W Wormald, MBBS BSc</last_name>
    <phone>02086616101</phone>
    <email>Ben.wormald@icr.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nandita DeSouza, MD</last_name>
    <phone>02086613119</phone>
    <email>Nandita.desouza@icr.ac.uk</email>
  </overall_contact_backup>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2017</study_first_submitted>
  <study_first_submitted_qc>December 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2017</study_first_posted>
  <last_update_submitted>December 15, 2017</last_update_submitted>
  <last_update_submitted_qc>December 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

